Compare ANIX & CHMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANIX | CHMI |
|---|---|---|
| Founded | 1982 | 2012 |
| Country | United States | United States |
| Employees | N/A | 14 |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 108.5M | 95.5M |
| IPO Year | 2013 | N/A |
| Metric | ANIX | CHMI |
|---|---|---|
| Price | $3.39 | $2.37 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $8.67 | $3.00 |
| AVG Volume (30 Days) | ★ 282.9K | 211.4K |
| Earning Date | 05-27-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 15.09% |
| EPS Growth | ★ 12.82 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $210,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $61.13 |
| P/E Ratio | ★ N/A | $139.30 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.32 | $2.17 |
| 52 Week High | $5.46 | $3.04 |
| Indicator | ANIX | CHMI |
|---|---|---|
| Relative Strength Index (RSI) | 62.87 | 51.90 |
| Support Level | $2.90 | $2.33 |
| Resistance Level | $3.53 | $2.46 |
| Average True Range (ATR) | 0.28 | 0.06 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 79.92 | 43.75 |
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
Cherry Hill Mortgage Investment Corp is a fully integrated, internally managed residential real estate finance company focused on acquiring, investing in and managing residential mortgage assets in the United States. It invests in residential mortgage assets to generate current yields and risk-adjusted total returns for its stockholders over the long term, through dividend distributions and secondarily through capital appreciation. The company's reportable segments include investments in Residential mortgage-backed securities (RMBS), Investments in Servicing Related Assets, and All Others. It generates maximum revenue from the RMBS segment in the form of Interest income earned for servicing mortgage loans.